drugset / Trial / NCT00869622
Antiepileptic Drugs and Osteoporotic Prevention Trial
Phase 4
Completed
80 enrolled
Boston VA Research Institute, Inc.
Alliance for Better Bone Health · collabProcter and Gamble · collabVA Boston Healthcare System · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel): Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone loss associated with the use of antiepileptic drugs.
Timeline
- Start
- 2006-06
- Primary completion
- 2012-10
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risedronate | Small molecule | 35 mg | Oral |
| Comparator | Calcium carbonate | Other / unclassified | 1200 mg | — |
| Comparator | Vitamin D | Other / unclassified | 800 iu | — |